當(dāng)前位置:首頁 >產(chǎn)品中心>細(xì)胞庫>人正常細(xì)胞>CLHKMR01美國人鹽皮質(zhì)激素受體可誘導(dǎo)表達細(xì)胞株
簡要描述:美國Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達細(xì)胞株:美國PrimCells誘導(dǎo)性穩(wěn)定細(xì)胞株: PrimCells建立的*的誘導(dǎo)性細(xì)胞高效開發(fā)系統(tǒng),能在極短時間內(nèi)篩選出低泄漏,高誘導(dǎo)性的穩(wěn)定細(xì)胞株,成功開發(fā)出一系列核受體誘導(dǎo)表達的穩(wěn)定細(xì)胞株產(chǎn)品,為多家制藥公司研發(fā)部門和科研院所提供產(chǎn)品與服務(wù),廣受用戶好評。針對客戶的特定需求,PrimCells亦提供量身定
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
美國Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達細(xì)胞株
美國PrimCells誘導(dǎo)性穩(wěn)定細(xì)胞株: PrimCells建立的*的誘導(dǎo)性細(xì)胞高效開發(fā)系統(tǒng),能在極短時間內(nèi)篩選出低泄漏,高誘導(dǎo)性的穩(wěn)定細(xì)胞株,成功開發(fā)出一系列核受體誘導(dǎo)表達的穩(wěn)定細(xì)胞株產(chǎn)品,為多家制藥公司研發(fā)部門和科研院所提供產(chǎn)品與服務(wù),廣受用戶好評。針對客戶的特定需求,PrimCells亦提供量身定制服務(wù),通過密切的客戶交流和高效的篩選體系,嚴(yán)格保證客戶在3-4周內(nèi)即獲得高質(zhì)量的誘導(dǎo)性穩(wěn)定細(xì)胞株,具有市場其他供應(yīng)商*的時效性。
Introduction:
Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical research. PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, flag- and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.
f-hMR/HEK293 cell line was created by stable co-transfection of HEK293 cells with two plasmids expressing the bacterial Tet repressor (TetR) and the human mineralocorticoid receptor (hMR) proteins. Since the hMR gene is driven by a promoter containing two tetracycline operator (TeTO2) sites, the expression of hMR protein can be induced by doxycycline.
美國Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達細(xì)胞株
Figure 1 | Confirmed hMR Expression in f-hMR stable cells
美國PrimCells品牌介紹
PrimCells是位于美國加州圣迭戈的一家專業(yè)致力于細(xì)胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)。
公司匯集了*的生物醫(yī)藥技術(shù)專家,獨立開發(fā)了多項原代細(xì)胞和干細(xì)胞相關(guān)的專有技術(shù)。 公司以“細(xì)胞研究的優(yōu)選擇"為宗旨,自主研發(fā)超過70種創(chuàng)新產(chǎn)品,多個特種細(xì)胞市場的空白。例如其誘導(dǎo)性表達細(xì)胞庫和高效3D皮膚培養(yǎng)系統(tǒng),皆為該類產(chǎn)品目前市場上少數(shù)的規(guī)模化供應(yīng)商。此外,公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項目完成時間,長期為多家制藥公司提供解決方案,獲得用戶廣泛贊譽。
PrimCells產(chǎn)品線:
報告基因干細(xì)胞 2. 原代細(xì)胞(含報告基因原代細(xì)胞) 3. 誘導(dǎo)性穩(wěn)定細(xì)胞株
4. 人源重組蛋白 5. 創(chuàng)新型培養(yǎng)試劑
PrimCells 解決方案
1.誘導(dǎo)性穩(wěn)定細(xì)胞株開發(fā) 2. 原代細(xì)胞開發(fā) 3. 藥物體外毒理和效能測試 4. 3D-皮膚培養(yǎng)
PrimCells合作伙伴及客戶:
A.生物制藥公司:輝瑞(Pfizer), 諾華(Novartis), 禮來(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門
B.科研機構(gòu):冷泉港實驗室,哈佛醫(yī)學(xué)院, 麻省理工(MIT),, UCSF, NYU, Salk, UIUC, USC等
美國Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達細(xì)胞株
產(chǎn)品咨詢
郵箱:xiangfbio@163.com
地址:上海市虹口區(qū)四平路710號7層
掃一掃 微信咨詢